Evidence map›Paper›PMID 26201523›Full record

ArticleHepatology international2012

Entecavir treatment prevents disease progression in hepatitis B virus-related acute-on-chronic liver failure: establishment of a novel logistical regression model.

Ke Ma, Wei Guo, Meifang Han, Guang Chen, Tao Chen, Zenguang Wu, Daofeng Yang, Jiaquan Huang, Yuancheng Huang, Xiping Zhao and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Hepatology international, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 37 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. [Expert consensus on diagnosis and treatment of end-stage liver disease complicated infection (2021 version)].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. [Expert consensus on diagnosis and treatment of end-stage liver disease complicated with infections].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2018
    Article
  17. Chronic Hepatitis B with Spontaneous Severe Acute Exacerbation.International journal of molecular sciences · 2015
    Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Ke MaDepartment of Infectious Disease, Tongji Hospital, Tongji Medical College, University of Science and Technology, No 1095, Jiefang Avenue, 430030, Wuhan, China.
Wei GuoDepartment of Infectious Disease, Tongji Hospital, Tongji Medical College, University of Science and Technology, No 1095, Jiefang Avenue, 430030, Wuhan, China.
Meifang HanDepartment of Infectious Disease, Tongji Hospital, Tongji Medical College, University of Science and Technology, No 1095, Jiefang Avenue, 430030, Wuhan, China.
Guang ChenDepartment of Infectious Disease, Tongji Hospital, Tongji Medical College, University of Science and Technology, No 1095, Jiefang Avenue, 430030, Wuhan, China.
Tao ChenDepartment of Infectious Disease, Tongji Hospital, Tongji Medical College, University of Science and Technology, No 1095, Jiefang Avenue, 430030, Wuhan, China.
Zenguang WuDepartment of Infectious Disease, Tongji Hospital, Tongji Medical College, University of Science and Technology, No 1095, Jiefang Avenue, 430030, Wuhan, China.
Daofeng YangDepartment of Infectious Disease, Tongji Hospital, Tongji Medical College, University of Science and Technology, No 1095, Jiefang Avenue, 430030, Wuhan, China.
Jiaquan HuangDepartment of Infectious Disease, Tongji Hospital, Tongji Medical College, University of Science and Technology, No 1095, Jiefang Avenue, 430030, Wuhan, China.
Yuancheng HuangDepartment of Infectious Disease, Tongji Hospital, Tongji Medical College, University of Science and Technology, No 1095, Jiefang Avenue, 430030, Wuhan, China.
Xiping ZhaoDepartment of Infectious Disease, Tongji Hospital, Tongji Medical College, University of Science and Technology, No 1095, Jiefang Avenue, 430030, Wuhan, China.
Deying TianDepartment of Infectious Disease, Tongji Hospital, Tongji Medical College, University of Science and Technology, No 1095, Jiefang Avenue, 430030, Wuhan, China.
Jianxin SongDepartment of Infectious Disease, Tongji Hospital, Tongji Medical College, University of Science and Technology, No 1095, Jiefang Avenue, 430030, Wuhan, China.
Junying QiDepartment of Infectious Disease, Tongji Hospital, Tongji Medical College, University of Science and Technology, No 1095, Jiefang Avenue, 430030, Wuhan, China.
Qin NingDepartment of Infectious Disease, Tongji Hospital, Tongji Medical College, University of Science and Technology, No 1095, Jiefang Avenue, 430030, Wuhan, China. qning@tjh.tjmu.edu.cn.
Huazhong University of Science and Technology · CNTongji Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatitis B-related acute-on-chronic liver failure (ACLF) has a poor prognosis with very high mortality. Unfortunately, most prognostic predictive models of liver failure are complicated and offer suboptimal sensitivity. Experience in entecavir (ETV)-treated patients with hepatitis B virus (HBV)-ACLF is limited.

aimsThis study was designed to evaluate the efficacy and safety of ETV in patients with HBV-ACLF and to develop a novel model (Tongji prognostic predictor model, TPPM) for prognostic prediction of HBV-ACLF patients.

methodIn this retrospective study, 248 patients with HBV-ACLF were enrolled. There were no significant differences in baseline clinical and virologic characteristics between patients treated with and without ETV.

resultsThe 1- and 3-month survival rates of patients in the ETV-treated group (n = 124) were 72.58 and 61.29%, respectively, significantly higher than that in NA-free group (n = 124), which were 53.23 and 45.97%, respectively. By Hosmor and Lemeshow test, TPPM for HBV-ACLF had a very good degree of fit with disease prognosis. Based on this unique group of patients, the TPPM scoring offered a better prediction value in both specificity and sensitivity for 3-month mortality of patients with HBV-ACLF compared with MELD scoring system with statistically significant difference. In the patients with HBV-ACLF, using a cutoff of 0.22 for 3-month predicted mortality by TPPM, the positive predictive value was 93.6% and negative predictive value 91.3%.

conclusionETV treatment prevented disease progression and increased the survival of patients with HBV-ACLF. The established TPPM scoring system offers superior predictor value in both specificity and sensitivity for HBV-ACLF patients when compared with MELD.

Indexed as

Acute-on-chronic liver failureEntecavirHepatitis B virusScoring model

Identifiers

PMID26201523
OpenAlexW2027000272

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.